Feasibility of Continuous Ketone Monitoring in Subcutaneous Tissue Using a Ketone Sensor.

continuous ketone monitoring diabetes ketoacidosis factory calibration ketogenic β-hydroxybutyrate

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 10 4 2021
medline: 29 10 2021
entrez: 9 4 2021
Statut: ppublish

Résumé

The feasibility of measuring β-hydroxybutyrate in ISF using a continuous ketone monitoring (CKM) sensor using a single calibration without further adjustments over 14 days is described. A CKM sensor was developed using wired enzyme technology with β-hydroxybutyrate dehydrogenase chemistry. In vitro characterization of the sensor was performed in phosphate buffered saline at 37°C. In vivo performance was evaluated in 12 healthy participants on low carbohydrate diets, who wore 3 ketone sensors on the back of their upper arms to continuously measure ketone levels over 14 days. Reference capillary ketone measurements were performed using Precision Xtra® test strips at least 8 times a day. The sensor is stable over 14 days and has a linear response over the 0-8 mM range. The operational stability of the sensor is very good with a 2.1% signal change over 14 days. The first human study of the CKM sensor demonstrated that the sensor can continuously track ketones well through the entire 14 days of wear. The performance with a single retrospective calibration of the sensor showed 82.4% of data pairs within 0.225 mM/20% and 91.4% within 0.3 mM/30% of the capillary ketone reference (presented as mM at <1.5 mM and as percentage at or above 1.5 mM). This suggests that the sensor can be used with a single calibration for the 14 days of use. Measuring ketones in ISF using a continuous ketone sensor is feasible. Additional studies are required to evaluate the performance in intended patient populations, including conditions of ketosis and diabetic ketoacidosis.

Sections du résumé

BACKGROUND
The feasibility of measuring β-hydroxybutyrate in ISF using a continuous ketone monitoring (CKM) sensor using a single calibration without further adjustments over 14 days is described.
METHODS
A CKM sensor was developed using wired enzyme technology with β-hydroxybutyrate dehydrogenase chemistry. In vitro characterization of the sensor was performed in phosphate buffered saline at 37°C. In vivo performance was evaluated in 12 healthy participants on low carbohydrate diets, who wore 3 ketone sensors on the back of their upper arms to continuously measure ketone levels over 14 days. Reference capillary ketone measurements were performed using Precision Xtra® test strips at least 8 times a day.
RESULTS
The sensor is stable over 14 days and has a linear response over the 0-8 mM range. The operational stability of the sensor is very good with a 2.1% signal change over 14 days. The first human study of the CKM sensor demonstrated that the sensor can continuously track ketones well through the entire 14 days of wear. The performance with a single retrospective calibration of the sensor showed 82.4% of data pairs within 0.225 mM/20% and 91.4% within 0.3 mM/30% of the capillary ketone reference (presented as mM at <1.5 mM and as percentage at or above 1.5 mM). This suggests that the sensor can be used with a single calibration for the 14 days of use.
CONCLUSIONS
Measuring ketones in ISF using a continuous ketone sensor is feasible. Additional studies are required to evaluate the performance in intended patient populations, including conditions of ketosis and diabetic ketoacidosis.

Identifiants

pubmed: 33832353
doi: 10.1177/19322968211008185
pmc: PMC8252149
doi:

Substances chimiques

Blood Glucose 0
Ketones 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

768-774

Références

Anal Chem. 2020 Jan 21;92(2):2291-2300
pubmed: 31874029
J Diabetes Sci Technol. 2019 Sep;13(5):967-973
pubmed: 30628470
Spec Top Endocrinol Metab. 1982;4:1-27
pubmed: 6820732
Cardiovasc Diabetol. 2020 Dec 8;19(1):208
pubmed: 33292205
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26
pubmed: 10634967
Front Psychol. 2015 Feb 02;6:27
pubmed: 25698989
Intern Med J. 2018 Sep;48(9):1080-1086
pubmed: 29573166
J Diabetes Sci Technol. 2013 Sep 01;7(5):1210-9
pubmed: 24124948
Diabet Med. 2006 Mar;23(3):278-84
pubmed: 16492211
Diabetes Care. 2015 Jun;38(6):971-8
pubmed: 25998289
Diabet Med. 2001 Aug;18(8):640-5
pubmed: 11553201
Nutr Metab (Lond). 2008 Dec 19;5:36
pubmed: 19099589
Adv Pediatr. 2010;57(1):247-67
pubmed: 21056741
Diabetes Care. 2020 May;43(5):1146-1156
pubmed: 32312858
Int J Environ Res Public Health. 2014 Feb 19;11(2):2092-107
pubmed: 24557522
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3704-9
pubmed: 8623000
Diabetes Technol Ther. 2010 Aug;12(8):591-7
pubmed: 20615099
N Engl J Med. 2015 Feb 5;372(6):546-54
pubmed: 25651248
Am J Clin Nutr. 2002 Jul;76(1):65-70
pubmed: 12081817
J Neurochem. 2012 Apr;121(1):28-35
pubmed: 22268909
J Diabetes Investig. 2016 Mar;7(2):135-8
pubmed: 27042263

Auteurs

Shridhara Alva (S)

Abbott Diabetes Care, Alameda, CA, USA.

Kristin Castorino (K)

Sansum Diabetes Research Institute, Santa Barbara, CA, USA.

Hyun Cho (H)

Abbott Diabetes Care, Alameda, CA, USA.

Junli Ou (J)

Abbott Diabetes Care, Alameda, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH